Disposition of valproic acid in self-poisoned adults

Basic and Clinical Pharmacology and Toxicology

Volumn 99, Issue 1, 2006, Pages 22-26

  Wilimowska, Jolanta ^a   Florek, Ewa ^b   Piekoszewski, Wojciech ^c  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c INSTITUTE OF FORENSIC RESEARCH   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BARBITURIC ACID DERIVATIVE; CHLORPROTHIXENE; CLOMIPRAMINE; PHENOBARBITAL; PROTEIN; TETRAHYDROCANNABINOL; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; CALCULATION; CLINICAL ARTICLE; CLINICAL PRACTICE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INTOXICATION; FEMALE; HUMAN; MALE; POLAND; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; SELF POISONING;

ADOLESCENT; ADULT; ANTICONVULSANTS; BLOOD PROTEINS; COMA; DRUG INTERACTIONS; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GLASGOW COMA SCALE; HALF-LIFE; HUMANS; IMMUNOENZYME TECHNIQUES; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; PROTEIN BINDING; SUICIDE, ATTEMPTED; VALPROIC ACID;

EID: 33745813200     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.pto_417.x     Document Type: Article

References (37)

1. Al-Shareef, A., D. C. Buss, H. G. M. Shetty, N. Ali & P. A. Routledge: The effect of repeated dose activated charcoal on pharmacokinetic of sodium valproate in healthy volunteers. Brit. J. Clin. Pharm. 1997, 43, 109-111.
2. Anderson, G. D.: Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 2002, 43, (suppl. 3), 53-59.
3. Anderson, G. & S. Ritland: Life treating intoxication with sodium valproate. J. Toxicol. Clin. Toxicol. 1995, 33, 279-284.
4. Brubacher, J. R., P. Dahghani & D. McKnight: Valoproic acid toxicity following ingestion of enteric-coated divalproex sodium (Epival). J. Emergency Med. 1999, 17, 463-467.
5. Davis, L. L., W. Ryan, B. Adinoff & F. Petty: Comprehensive review of the psychiatric use of valproate. J. Clin. Psychopharmacol. 2000, 20, (suppl. 1), 1S-7S.
6. DeToledo, J. C., H. Haddad & R. E. Ramsay: Status epilepticus with the combination of valproic acid and clomipramine. Therap. Drug Monitor. 1997, 19, 71-73.
7. DeVane, C. L.: Pharmacokinetics, drug interaction, and tolerability of valproate. Psychopharmacol. Bull. 2003, 37, (suppl. 2), 25-42.
8. Dupuis, R. E., S. N. Lichtman & G. M. Pollack: Acute valproic acid overdose. Clinical course and pharmacokinetic disposition of valproic acid and metabolites. Drug Safety 1990, 5, 65-71.
9. Engberson, R. C. Kramers: Enhanced extracorpal elimination of valproic acid in overdose. Neth. J. Med. 2004, 62, 307-308.
10. Fehr, C., G. Grunder, C. Hiemke & N. Dahmen: Increase in serum clomipramine concentrations caused by valproate. J. Clin. Psychopharmacol. 2000, 20, 493-494.
11. Fowler, G. W.: Effect dipropyloacetate on serum level of anticonvulsants in children. Proc. West Pharmacological Society 1978, 23, 37.
12. Franssen, E. J. F., C. G. van Essen, A. T. Portman, J. de Jong, G. Go, C. A. Stegeman & D. R. A. Uges: Valproic acid toxicokinetics: serial hemodialysis and hemoperfusion. Therap. Drug Monitor. 1999, 21, 289-294.
13. Goldberg, J. F: Treatment guidelines: current and future management of bipolar disorder. J. Clin. Psychiatry 2000, 61, (suppl. 13), 12-18.
14. Graudins, A. & C. K. Aaron: Delay peak serum valproic acid in massive divalprox overdose-treatment with charcoal hemoperfusion. J. Toxicol. Clin. Toxicol. 1996, 34, 335-341.
15. Gugler, R., A. Schell, M. Eichelbaum, W. Froscher & H. U. Schultz: Disposition of valproic acid in man. Eur. J. Clin. Pharmacol. 1977, 12, 125-132.
16. Hamer, H. M., S. Kanaka, M. A. Schomburg & V. Rosenof: Valproate-induced hyperammonemic encephalopathy in the presence of topiramine. Neurology 2000, 54, 230-232.
17. Hardy, J. R., E. A. J. Rees, B. Gwillian, J. Ling, K. Broadly & R. A'Hern: A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain. J. Pain Symptom Management 2001, 21, 204-209.
18. Ingelis, M., C. Johnson, C. Rangan, L. Cantrell, J. Beauchamp & R. F. Clark: Retrospective study of delayed valproic acid toxicity. Acad. Emergency Med. 2000, 7, 499.
19. Isbister, G. K., C. R. Balit, I. M. Whyte & A. Dawson: Valproate overdose: a comparative cohort study of self poisoning. Brit. J. Clin. Pharmacol. 2003, 55, 398-404.
20. Jacobs, C. & W. Loscher: Identification of metabolites of valproic acid in serum of humans, dog, rat and mouse. Epilepsia 1978, 19, 591-602.
21. Johnson, L. Z., I. Martinez, M. C. Fernandez, C. P. Davis & B. S. Kasinath: Successful treatment of valproic acid overdose with hemodialysis. Amer. J. Kidney Diseases 1999, 33, 786-789.
22. Kodama, Y: Protein binding of valproic acid in Japanese paediatric and adult patients with epilepsy. Amer. J. Health System Pharm. 2002, 59, 835-840.
23. Meek, M. F., J. Broekroelofs, J. P. Yska, P. H. Egbers, E. C. Boerma & P. H. van der Voort: Valproic acid intoxication: sens and non-sens of hemodialysis. Neth. J. Med. 2004, 62, 333-336.
24. McLaughin, D. B., M. J. Eadie, S. L. Parker-Scot, R. S. Addison, R. D. Henderson, W. D. Hooper & R. G. Dicson: Valproate metabolism during valoprate-associated hepatotoxicity in surviving adult patients. Epilepsy Res. 2000, 41, 259-268.
25. Minville, V., C. Roch Tissot & K. Samii: Haemodialysis, L-carnitine therapy and valproic acid overdose. Ann. Fr. Anesth. Reanim. 2004, 23, 357-360.
26. Morrow, J. L. & P. A. Routledge: Poisoning by anticonvulsants. Adverse Drug Reaction Acute Poisoning Reviws 1989, 8, 97-109.
27. Nau, H. & W. Wittfoht: Vaproic acid and several metabolites: quantitative determination in serum, urine, breast milk and tissue by gas chromatography-mass spectrometry using selected ion monitoring. J. Chromatogr. 1981, 226, 69-78.
28. Nau, H. & W. Loscher: Valproic acid and metabolites pharmacological and toxicological stydies. Epilepsia 1984, 25, (suppl. 1), S14-S22.
29. Norton, J., Use of intravenous valproate sodium in status migraine. Headache 2000, 40, 755-757.
30. Patsalos, P. & E. Perucca: Clinically important drug interaction in epilepsy: general feature and interaction between antiepileptic drugs. Lancet Neurology 2003, 2, 347-356.
31. Pisani, F.: Influence of co-medication on the metabolism of valproate. Pharmacy Weekblad Science 1992, 14, 108-113.
32. Riva, R., F. Albeni, M. Conti & A. Baruzzi: Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations. Clin. Pharmacokin. 1996, 31, 470-493.
33. Spiller, H. A., E. P. Krenzelok, W. Klein-Schwartz, M. L. Winter, J. A. Weber, D. R. Sollee & S. A. Bangh: Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. Clin. Toxicol. 2000, 38, 755-760.
34. Sztajnkrycer, M. D.: Valproic acid toxicity: overview and management. Clin. Toxicol. 2002, 40, 789-801.
35. Tartara, A., C. A. Galimberti, R. Manni, L. Parietti, C. Zucca, H. Baasch, L. Caresia, W. Muck, N. Barzanghi, G. Gatti & E. Perucca: Differential effects of valproic acide and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. Brit. J. Clin. Pharm. 1991, 32, 335-340.
36. Yukava, E.: Investigation of phenobarbital-carbamazepine-valproic acid interaction using population pharmacokinetic analysis for optimisation of antiepileptic drug therapy: an overview. Drug Metab. Drug Interact. 2000, 16, 86-98.
37. Zaccara, G., A. Messori & F. Moroni: Clinical pharmacokinetics of valproic acid. Clin. Pharmacokin. 1988, 15, 367-389.